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Colorectal cancer (CRC) remains as a major cause of mortality in the developed 
countries due to the absence of appropriate biomarkers for diagnosis. Progression 
to metastasis is the critical point in colorectal cancer survival. Metastasis of CRC is 
very poorly understood at the moment. In previous studies, the use of 2D-DIGE and 
antibody microarrays led to the identification of differentially-expressed proteins in 
primary CRC tumors as potential specific biomarkers of CRC. Both approaches were 
complementary and enabled us to identify a large collection of potential tumoral tissue 
biomarkers that is being currently investigated. These proteins included isoforms and 
post-translational modifications responsible for modifications in signalling pathways.
Recently, we have been working along two different lines for the search of colorectal 
cancer biomarkers related with metastasis: On the one hand, two colorectal cancer cell 
lines (KM12C and KM12SM), representing non-metastatic versus highly metastatic 
cells were compared to find and quantify the differences in protein expression at the 
cell surface level by using a SILAC approach. We were able to identify 291 membrane 
and membrane associated proteins from these two cell lines. A total of 66 proteins were 
differentially expressed more than 1.5-fold. Together with CEA and EGFR we identified 
an elevated number of cell receptors, CDs and cell adhesion molecules among the most 
deregulated proteins in metastatic cells. These proteins were further validated by using 
different techniques.
On the other hand, we have used high density protein microarrays comprising 8000 
human proteins to identify autoantibody signatures in the sera of CRC patients. The 
screening was performed using sera from CRC patients in advanced stages, including 
metastasis. A total of 43 proteins were differentially recognized with a statistically 
significant value p < 0.04, 26 proteins showed higher prevalence in CRC sera and 17 
showed lower prevalence. Furthermore, an ELISA assay was developed using these 
purified recombinant proteins for testing their discriminatory power in a different subset 
of human sera. The results confirmed the presence of a discriminatory autoantibody 
signature for CRC diagnosis and point out new individual markers of disease with a 
potential diagnostic capacity in metastasis.
